BRPI0615481A2 - peptídeos antigênicos e sua utilização - Google Patents

peptídeos antigênicos e sua utilização

Info

Publication number
BRPI0615481A2
BRPI0615481A2 BRPI0615481A BRPI0615481A BRPI0615481A2 BR PI0615481 A2 BRPI0615481 A2 BR PI0615481A2 BR PI0615481 A BRPI0615481 A BR PI0615481A BR PI0615481 A BRPI0615481 A BR PI0615481A BR PI0615481 A2 BRPI0615481 A2 BR PI0615481A2
Authority
BR
Brazil
Prior art keywords
antigenic peptides
antigenic
peptides
Prior art date
Application number
BRPI0615481A
Other languages
English (en)
Inventor
Corradin Giampietro
Jafarshad Ali
Kajava Andrey
Pierre Druilhe
Original Assignee
Pasteur Institut
Univ Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Univ Lausanne filed Critical Pasteur Institut
Publication of BRPI0615481A2 publication Critical patent/BRPI0615481A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BRPI0615481A 2005-08-19 2006-08-16 peptídeos antigênicos e sua utilização BRPI0615481A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05018052A EP1754717A1 (en) 2005-08-19 2005-08-19 Antigenic peptides and their use
PCT/IB2006/002232 WO2007020520A2 (en) 2005-08-19 2006-08-16 Antigenic peptides and their use

Publications (1)

Publication Number Publication Date
BRPI0615481A2 true BRPI0615481A2 (pt) 2016-10-11

Family

ID=35447897

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0615481A BRPI0615481A2 (pt) 2005-08-19 2006-08-16 peptídeos antigênicos e sua utilização

Country Status (7)

Country Link
US (1) US20090053265A1 (pt)
EP (2) EP1754717A1 (pt)
CN (1) CN101287752A (pt)
BR (1) BRPI0615481A2 (pt)
CA (1) CA2619716A1 (pt)
WO (1) WO2007020520A2 (pt)
ZA (1) ZA200801874B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
NZ583150A (en) * 2007-08-13 2012-05-25 Glaxosmithkline Biolog Sa Use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum in the manufacture of a medicament for vaccinating infants against malaria
EP2116261A1 (en) 2008-05-07 2009-11-11 Institut Pasteur Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
US9795661B2 (en) 2009-11-16 2017-10-24 The United States Of America As Represented By The Secretary Of The Navy TH1/TH2 polarizing vaccines
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8706599D0 (en) * 1987-03-19 1987-04-23 Hoffmann La Roche Plasmodium falciparum merozoite antigen peptides
DE3737238A1 (de) 1987-11-03 1989-05-18 Behringwerke Ag Rekombinantes histidinreiches protein (37 kd antigen) von plasmodium falciparum, seine herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5840695A (en) * 1994-10-07 1998-11-24 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
AU762945B2 (en) * 1998-08-21 2003-07-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant multivalent malarial vaccine against plasmodium falciparum
ATE422899T1 (de) 1998-12-21 2009-03-15 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
EP1290019A2 (en) 2000-06-14 2003-03-12 Cytovax Biotechnologies Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides

Also Published As

Publication number Publication date
CN101287752A (zh) 2008-10-15
WO2007020520A2 (en) 2007-02-22
CA2619716A1 (en) 2007-02-22
EP1919940A2 (en) 2008-05-14
EP1754717A1 (en) 2007-02-21
WO2007020520A3 (en) 2007-06-21
US20090053265A1 (en) 2009-02-26
ZA200801874B (en) 2009-03-25

Similar Documents

Publication Publication Date Title
NO20080692L (no) SP35 antistoffer og anvendelse derav
CY2016023I2 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9 (pcsk9)
DK1844074T3 (da) Humane antistoffer og proteiner
DK1894567T3 (da) Ledsagende farmaceutiske midler og anvendelse deraf
DK3295967T3 (da) Sårplejeindretning
BRPI0717367A2 (pt) Di-hidropirazolonas substituídas e sua aplicação.
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK1610820T4 (da) Høj-koncentration antistof- og proteinformuleringer
BRPI0818288A2 (pt) Proteínas conjugadas e peptídeos.
DK1599504T3 (da) Modificeret antistof
DE602006003063D1 (de) Tripeptid- und tetrapeptidsulfone
DE502005000353D1 (de) Mikroschalter
DE602004012563D1 (de) Mehrfädiges DMA
DK1840121T3 (da) Glycinderivat og anvendelse heraf
DK1809660T3 (da) Thymus-specifikt protein
FI20061043A (fi) Selän hoitolaite
DK1968623T3 (da) Bacteriocin-inducer-peptider
ATE520982T1 (de) Immuntest
BRPI0615481A2 (pt) peptídeos antigênicos e sua utilização
DK1812072T3 (da) Benzothiazol-præparat og anvendelse deraf
FI20041538A0 (fi) Goniometri
DK1625148T3 (da) Peptidkompleks
ITMI20040033A1 (it) Imbottitura e procedimento per la sua realizzazione
SE0402638D0 (sv) Pharmaceutical use
SE0402678D0 (sv) Pharmaceutical use

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 16080001065/RS DE 19/02/2008.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B25A Requested transfer of rights approved

Owner name: UNIVERSITE DE LAUSANNE (CH) , INSTITUT PASTEUR (FR

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]